Jade Biosciences, Inc. Common Stock (JBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, JBIO trades at $23.63 with a market cap of $1.09B and a P/E ratio of -7.26. JBIO moved +6.35% today. Year to date, JBIO is +77.90%; over the trailing twelve months it is +202.53%. Its 52-week range spans $6.57 to $28.00. Analyst consensus is strong buy with an average price target of $35.67. Rallies surfaces JBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Recent JBIO insider activity includes Frohlich Tom bought 6.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
| Metric | Value |
|---|---|
| Price | $23.63 |
| Market Cap | $1.09B |
| P/E Ratio | -7.26 |
| EPS | $-3.19 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.00 |
| 52-Week Low | $6.57 |
| Volume | 105 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-127.41M |
| Gross Margin | 0.00% |
8 analysts cover JBIO: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.67.